Prime Medicine (PRME) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts4

Ratings

Updated Sep 12, 2026

Overall Rating

D+

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.13

Median Target+139.62%

$7.50

Potential upside vs current price

DCF Value-102.58%

-$0.08

Potential downside vs current price

Current Stock Price

$3.13

Median Target+139.62%

$7.50

Potential upside vs current price

DCF Value-102.58%

-$0.08

Potential downside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts4

Ratings

Updated Sep 12, 2026

Overall Rating

D+

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.13

Median Target+139.62%

$7.50

Potential upside vs current price

DCF Value-102.58%

-$0.08

Potential downside vs current price

Current Stock Price

$3.13

Median Target+139.62%

$7.50

Potential upside vs current price

DCF Value-102.58%

-$0.08

Potential downside vs current price

Prime Medicine, Inc.